Autologous Stem Cell Transplantation as Adjuvant Treatment vs No Further Therapy for Poor-Risk Hodgkin's Disease in First Complete Remission after MOPP/ABVD

Carelia, Angelo M.; Pollicardo, N.; Pungolino, Ester; Frassoni, Francesco; Gicrdano, Domenico; Bruni, Renato; Sprino, Mauro; Rossi, Edoardo

doi:10.3109/10428199509052709

Cited by 13 publications

(12 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The data suggest that transplantation has a superior outcome if the CR lasted less than 1 year. If the remission lasted longer than 1 year, recommendations In patients who underwent transplantation in first remission, 77% were in unmaintained remission with a median follow-up of 86 months (34-114 months) [37,38]. In the nonrandomized control group, with a median follow-up of 89 months, 33% were free of disease.…”

Section: Hdmentioning

confidence: 99%

High-Dose Therapy in Lymphomas: A Review of the Current Status of Allogeneic and Autologous Stem Cell Transplantation in Hodgkin's Disease and Non-Hodgkin's Lymphoma

Mink

Armitage

2001

The Oncologist

View full text Add to dashboard Cite

Autologous stem cell transplantation has proven to be beneficial in selected patients with Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL). In patients with HD, transplantation appears to increase event-free survival in patients who fail to enter complete remission with initial therapy. When a patient relapses after a complete remission, transplantation is probably the best option and particularly so if the remission lasted less than 1 year. Transplantation as part of primary therapy for very highrisk patients may be beneficial, but is not standard therapy at this time. For patients with diffuse large-cell NHL, transplantation can be considered standard therapy for relapsed patients if they have chemotherapy-sensitive disease. The use of transplantation for high-risk patients in complete remission is promising, but definite recommendations cannot be made at this time. For follicular lymphomas, selected patients seem to benefit and studies are ongoing. Finally, the use of allogeneic stem cell transplantation can be useful in a select group of younger patients.

show abstract

Section: Hdmentioning

confidence: 99%

High-Dose Therapy in Lymphomas: A Review of the Current Status of Allogeneic and Autologous Stem Cell Transplantation in Hodgkin's Disease and Non-Hodgkin's Lymphoma

Mink

Armitage

2001

The Oncologist

View full text Add to dashboard Cite

show abstract

“…A number of other groups have reported long-term EFS or DFS rates of greater than 75% for patients with poor-prognosis HD transplanted in first remission [39,40,41•]. Using the same adverse factors described by Carella et al [38], Nademanee et al [11•] reported that 100% of patients transplanted in first CR or PR were alive and disease-free at a median of 42.8 months of follow-up.…”

Section: Hodgkin's Diseasementioning

confidence: 82%

“…Carella et al [38] were the first to describe a significant survival advantage when HDT/ASCT was used to consolidate a first CR among patients with poor-prognosis HD. Fifteen such patients underwent HDT/ASCT after primary therapy with MOPP (mechlorethamine, Oncovin, procarbazine, and prednisone)/ABVD.…”

Section: Hodgkin's Diseasementioning

confidence: 99%

Upfront transplantation for poor-risk aggressive non-hodgkin lymphoma and hodgkin’s disease: Who benefits?

Kewalramani

Moskowitz

2001

Curr Oncol Rep

View full text Add to dashboard Cite

High-dose therapy with autologous stem-cell transplantation is the standard treatment for patients with relapsed or primary refractory Hodgkin's disease or non-Hodgkin lymphoma. The efficacy of the treatment in this setting has prompted extensive investigation of its role in upfront therapy for patients with a poor prognosis. Although the preliminary data appear promising, definitive results are still lacking, and upfront transplantation remains investigational. Newer regimens for the treatment of advanced-stage Hodgkin's disease appear to confer cure rates of approximately 85% to 90%. Thus, only a small minority of patients may potentially benefit from more aggressive therapy such as upfront transplantation. A reliable method of identifying these patients is yet to be determined. Upfront transplantation should be evaluated in these patients once they are identified.

show abstract

“…Most prognostic indices have been developed for patients with advanced HD, and efforts are underway to test more intensified treatment regimens in patients defined as "high-risk" based on these indices [1]. Unfortunately, each of the published indices includes different parameters, making it difficult to establish uniform entry criteria for new trials [2,3].…”

Section: Prognostic Factors In Hodgkin's Diseasementioning

confidence: 99%

Hodgkin’s disease: Prognostic factors and short-course regimens

Bartlett

Arackal

2000

Curr Oncol Rep

View full text Add to dashboard Cite

Both topics discussed in this review, prognostic factors and short-course regimens for Hodgkin's disease, have been the focus of recent research with the goal of developing tools and treatments that will result in the highest cure rates with the least long-term sequelae. A new "prognostic score" for advanced-stage Hodgkin's disease and several potential prognostic factors, including soluble CD30, soluble interleukin-2 receptor, activated cytotoxic T-lymphocytes, and Epstein-Barr virus, are discussed. Preliminary reports of short-course chemotherapy regimens with and without radiotherapy for all stages of Hodgkin's disease are summarized.

show abstract

Autologous Stem Cell Transplantation as Adjuvant Treatment vs No Further Therapy for Poor-Risk Hodgkin's Disease in First Complete Remission after MOPP/ABVD

Cited by 13 publications

References 3 publications

High-Dose Therapy in Lymphomas: A Review of the Current Status of Allogeneic and Autologous Stem Cell Transplantation in Hodgkin's Disease and Non-Hodgkin's Lymphoma

High-Dose Therapy in Lymphomas: A Review of the Current Status of Allogeneic and Autologous Stem Cell Transplantation in Hodgkin's Disease and Non-Hodgkin's Lymphoma

Upfront transplantation for poor-risk aggressive non-hodgkin lymphoma and hodgkin’s disease: Who benefits?

Hodgkin’s disease: Prognostic factors and short-course regimens

Contact Info

Product

Resources

About